For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Regenxbio Inc (NASDAQ: RGNX) was $14.95 for the day, down -0.66% from the previous closing price of $15.05. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 0.53 million shares were traded. RGNX stock price reached its highest trading level at $15.3063 during the session, while it also had its lowest trading level at $14.74.
Ratios:
Our analysis of RGNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.66 and its Current Ratio is at 2.66. In the meantime, Its Debt-to-Equity ratio is 1.66 whereas as Long-Term Debt/Eq ratio is at 1.35.
Upgrades & Downgrades
In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 09 ’25 when Simpson Curran sold 20,811 shares for $12.62 per share. The transaction valued at 262,635 led to the insider holds 216,162 shares of the business.
CURRAN M SIMPSON bought 20,811 shares of RGNX for $254,310 on Oct 09 ’25. On Sep 29 ’25, another insider, Simpson Curran, who serves as the Chief Executive Officer of the company, sold 7,624 shares for $10.03 each. As a result, the insider received 76,469 and left with 236,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 756815168 and an Enterprise Value of 750750144. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.69 while its Price-to-Book (P/B) ratio in mrq is 4.69. Its current Enterprise Value per Revenue stands at 4.654 whereas that against EBITDA is -5.395.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.06, which has changed by 1.1048951 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $15.84, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 14.34%, while the 200-Day Moving Average is calculated to be 47.95%.
Shares Statistics:
RGNX traded an average of 638.33K shares per day over the past three months and 806620 shares per day over the past ten days. A total of 50.62M shares are outstanding, with a floating share count of 45.57M. Insiders hold about 9.98% of the company’s shares, while institutions hold 82.38% stake in the company. Shares short for RGNX as of 1767139200 were 4968961 with a Short Ratio of 7.78, compared to 1764288000 on 5424408. Therefore, it implies a Short% of Shares Outstanding of 4968961 and a Short% of Float of 11.91.
Earnings Estimates
Regenxbio Inc (RGNX) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.39, with high estimates of -$1.21 and low estimates of -$1.58.
Analysts are recommending an EPS of between -$1.67 and -$4.11 for the fiscal current year, implying an average EPS of -$3.24. EPS for the following year is -$2.05, with 8.0 analysts recommending between $1.61 and -$5.07.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $153.93M to a low estimate of $20M. As of. The current estimate, Regenxbio Inc’s year-ago sales were $21.21MFor the next quarter, 9 analysts are estimating revenue of $68.02M. There is a high estimate of $276.57M for the next quarter, whereas the lowest estimate is $20.48M.
A total of 10 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $310.14M, while the lowest revenue estimate was $160.1M, resulting in an average revenue estimate of $202.91M. In the same quarter a year ago, actual revenue was $83.33MBased on 10 analysts’ estimates, the company’s revenue will be $273M in the next fiscal year. The high estimate is $389M and the low estimate is $146.22M.
